跳转至内容
Merck
CN

H1428000

羟钴胺

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

关于此项目

经验公式（希尔记法）:
C62H89CoN13O15P
CAS Number:
13422-51-0
分子量:
1346.36
UNSPSC代码:
41116107
NACRES:
NA.24

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

pharmaceutical primary standard

API类

hydroxocobalamin

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

运输

wet ice

储存温度

−20°C

InChI

1S/C62H89N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H2,63,77)(H2,64,78)(H2,65,79)(H2,66,80)(H2,67,81)(H2,68,82)(H,69,83)(H,85,86);;1H2/q-2;+2;-1/p-1/t31-,34+,35+,36+,37-,41+,52+,53+,56?,57-,59+,60-,61-,62-;;/m0../s1

InChI key

PJOHJFIDLYDPIZ-PMEYKKDOSA-M

相关类别

一般描述

本品按现行药典规定交付。该产品的所有支持信息，包括SDS和任何产品信息宣传页均由药典发行机构制定并发布。如需更多信息和支持，请见现行药典的网站。

应用

羟钴胺EP参考标准品的预期用途是欧洲药典规定的实验室测试。

包装

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

其他说明

可能适用相应的销售限制。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Hydroxocobalamin hinders hemodialysis.
Samuel J Stellpflug et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 62(2), 395-395 (2013-06-19)
A man with tingling fingers.
Neal Larkman et al.
BMJ (Clinical research ed.), 346, f1443-f1443 (2013-03-20)
Zhuo Huang et al.
Zhonghua er ke za zhi = Chinese journal of pediatrics, 51(3), 194-198 (2013-06-12)
Combined methylmalonic acidemia with homocystinuria is a common form of methylmalonic acidemia in China. Patients with this disease can progress to death without timely and effective treatment. This study aimed to analyze the treatment outcomes of patients with combined methylmalonic
Emilie Cornec-Le Gall et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 63(1), 119-123 (2013-11-12)
A 20-year-old man was hospitalized for malignant hypertension, mechanical hemolysis, and kidney failure. Kidney biopsy confirmed glomerular and arteriolar thrombotic microangiopathy. Etiologic analyses, which included ADAMTS13 activity, stool culture, complement factor proteins (C3, C4, factor H, factor I, and MCP
I Vaz Matos et al.
Molecular genetics and metabolism, 109(4), 360-365 (2013-06-12)
CblC deficiency produces a combination of methylmalonic aciduria (MMA) and homocystinuria (HCU), and is the most common error of cobalamin metabolism. Patients present a wide spectrum of symptoms, ranging from early severe multisystemic forms, to milder late-onset phenotypes. Cognitive and
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持